Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million on February 26, 2024. As for consideration, purchase price comprises, $8 million upfront, which is payable at closing in the form of $2 million and $6 million in ordinary shares, equating to approximately 0.82 million ordinary shares, $5 million performance-related milestone payments, payable in cash, that are subject to meeting milestone conditions within twelve months of closing, and a two-year revenue share based on actual revenue earned from existing customers of IsoTherapeutics total estimated cash payments $0.6 million. Transaction is subject to Closing of the customary conditions, including regulatory approvals.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.49 AUD | +0.91% | +1.64% | +53.67% |
05-03 | Telix Pharmaceuticals Completes Acquisition of QSAM Biosciences and Drug Samarium-153-DOTMP | MT |
04-30 | Bell Potter Downgrades Telix Pharmaceuticals to Hold from Buy, Price Target is AU$14.50 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+53.67% | 3.38B | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- TLX Stock
- News Telix Pharmaceuticals Limited
- Telix Pharmaceuticals Limited entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million.